Trials / Completed
CompletedNCT00195442
Study Evaluating Refacto For Pharmacovigilance
Pharmacovigilance Evaluation Of Refacto In Usual Care Settings
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 288 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.
Detailed description
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moroctocog alfa | Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment. |
Timeline
- Start date
- 1999-07-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2005-09-19
- Last updated
- 2011-02-11
- Results posted
- 2011-02-07
Locations
26 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT00195442. Inclusion in this directory is not an endorsement.